Catechin-vanilloid synergies with potential clinical applications in cancer
D.M. Morré and D.J. Morré
Departments of Medicinal Chemistry & Molecular Pharmacology and Foods & Nutrition, Purdue University, West Lafayette, Indiana 47907, USA
Demographics predict future increases in cancer burden as the global
population grows and ages. These trends present challenges to develop
and implement improved anticancer strategies with absolute cancer
specificity and low or no toxicity to non-cancer cells and tissues.
Our work has identified a cancer-specific cell surface protein, tNOX,
as a target for low dose cell killing (apoptosis) of cancer cells by
green tea catechin and Capsicum vanilloid combinations. This
protein is unique in that it is associated with all forms of cancer and
is absent from normal cells and tissues. Activity of tNOX is
correlated with cancer growth and when blocked, cancer cells fail to
enlarge following division and eventually die. Among the most potent
and effective inhibitors of tNOX are naturally occurring polyphenols
exemplified by the principal green tea catechin (-)-epigallocatechin
gallate (EGCg) and the vanilloid capsaicin. Catechin-vanilloid
combinations are 10- to 100-times more effective than either catechins
or vanilloids alone. By combining vector-forced overexpression of tNOX
cDNA and antisense, we have demonstrated the tNOX target to be both
necessary and sufficient to explain the anticancer properties of green
tea catechins alone and in vanilloid-containing combinations. The
necessity and sufficiency of tNOX was validated as the catechin target
with transgenic mice overexpressing the processed form of tNOX. The
transgenic mice grew faster and the increased growth due to tNOX
overexpression was blocked by EGCg provided in the drinking water. A
catechin-vanilloid mixture where one 350 mg capsule is equivalent to 16
cups of green tea in its ability to inhibit tNOX and growth of cancer
cells in culture has been developed and is undergoing clinical
evaluation as a therapeutic aid for cancer patients.
Key words:
tNOX, cancer target, catechin-vanilloid synergies, transgenic, green tea
Problems or questions regarding this site should be directed to
the organiser